Table 3.

Multivariate analysis for DFS, DMFS and OS

Parameters	DFS		DMFS		OS
	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
Age (years)
≤35	1		1		/	/
>35	0.79 (0.51–1.21)	0.285	0.72 (0.47–1.11)	0.142	/
Tumor stage
T1	1		1		1
T2–4	2.32 (1.39–3.89)	0.001	2.31 (1.38–3.89)	0.001	2.73 (1.50–4.97)	<0.001
Tumor differentiation
I–II	1		1		1
III	2.42 (1.54–3.81)	<0.001	2.34 (1.49–3.66)	<0.001	1.85 (1.20–2.87)	0.005
Lymph node involvement
N0	1		1		1
N1–3	1.21 (0.77–1.87)	0.396	1.16 (0.75–1.81)	0.485	1.22 (0.75–2.00)	0.409
Surgery
Breast-conserving surgery	/		/		1
Radical mastectomy	/	/	/	/	1.58 (0.73–3.39)	0.238
Ki-67
≤30%	1		1		1
>30%	1.98 (1.36–2.68)	0.001	2.06 (1.74–3.92)	<0.001	2.31 (1.81–3.46)	<0.001
Lymphocytes
≤1.65	1		1		1
>1.65	0.76 (0.51–1.12)	0.174	0.72 (0.48–1.08)	0.116	0.62 (0.40–0.97)	0.039
NLR
≤2.3	1		1		1
>2.3	1.38 (0.96–1.99)	0.081	1.32 (0.92–1.91)	0.130	1.32 (0.90–1.95)	0.153
PLR
≤160	1		1		1
>160	1.23 (0.83–1.82)	0.296	1.36 (0.92–2.02)	0.114	1.34 (0.88–2.04)	0.167
SII
≤578	1		1		1
>578	1.46 (1.01–2.11)	0.045	1.40 (0.96–2.03)	0.078	1.51 (1.02–2.25)	0.038

Notes: Lymphocytes, NLR, and PLR are evaluated using the multivariate Cox regression for DFS, DMFS, and OS alongside other clinicopathological parameters that were found to be statistically significant after the univariate analysis. Only each of lymphocytes, NLR, and PLR alone are listed in this table.

Abbreviations: DFS, disease-free survival; DMFS, distant metastasis-free survival; OS, overall survival; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; SII, systemic immune-inflammation index.